Pasar al contenido principal

NUEVAS TERAPIAS PARA PATOLOGIAS OSEAS: FIBRODISPLASIA OSIFICANTE PROGRESIVA (FOP) Y OSTEOPOROSIS.

PID2020-117278GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUCNR1 signaling in adipocytes controls energy metabolism by modulating circadian clock and leptin expression

  • Villanueva-Carmona, Teresa
  • Cedó, Lídia
  • Madeira, Ana
  • Ceperuelo-Mallafré, Victoria
  • Rodríguez-Peña, M-Mar
  • Núñez-Roa, Catalina
  • Maymó-Masip, Elsa
  • Repollés-de-Dalmau, María
  • Badía, Joan
  • Keiran, Noelia
  • Mirasierra, Mercedes
  • Pimenta-Lopes, Carolina
  • Sabadell-Basallote, Joan
  • Bosch, Ramón
  • Caubet, Laura
  • Escolà-Gil, Joan Carles
  • Vilarrasa, Núria
  • Ventura, Francesc
  • Vallejo, Mario
  • Fernández-Veledo, Sonia
Adipose tissue modulates energy homeostasis by secreting leptin, but little is known about the factors governing leptin production. We show that succinate, long perceived as a mediator of immune response and lipolysis, controls leptin expression via its receptor SUCNR1. Adipocyte-specific deletion of Sucnr1 influences metabolic health according to nutritional status. Adipocyte Sucnr1 deficiency impairs leptin response to feeding, whereas oral succinate mimics nutrient-related leptin dynamics via SUCNR1. SUCNR1 activation controls leptin expression via the circadian clock in an AMPK/JNK-C/EBPα-dependent manner. Although the anti-lipolytic role of SUCNR1 prevails in obesity, its function as a regulator of leptin signaling contributes to the metabolically favorable phenotype in adipocyte-specific Sucnr1 knockout mice under standard dietary conditions. Obesity-associated hyperleptinemia in humans is linked to SUCNR1 overexpression in adipocytes, which emerges as the major predictor of adipose tissue leptin expression. Our study establishes the succinate/SUCNR1 axis as a metabolite-sensing pathway mediating nutrient-related leptin dynamics to control whole-body homeostasis., This study was supported by grants from the Spanish Ministry of Science and Innovation (MCIN)/AEI/10.13039/501100011033 (SAF2015-65019-R, RTI2018-093919-B-100, and PID2021-122480OB-I00 to S.F.-V.) and from the Instituto de Salud Carlos III (PI20/00095 to V.C.-M., and PI20/00338 to J.V.), all co-financed by the European Regional Development Fund (ERDF). This research was also supported by PID2020-119030RJ-I00 (to L. Cedó), PID2020-117640RB-I00 (to M.V.), and PID2020-117278GB-I00 (to F.V.) from MCIN/AEI/10.13039/501100011033. The project that gave rise to these results received funding from “La Caixa” Foundation under the grant agreement LCF/PR/HR20/52400013 (to S.F.-V.). N.V. is the recipient of grants “Ajuts per a projectes de recerca clínica de l’Hospital Universitari de Bellvitge (2011-PR143/11)” and the projects PI11/01960, PI14/01997, and PI17/01556 funded by the Instituto de Salud Carlos III and co-funded by “ERDF, A way to build Europe.” T.V.-C. is a recipient of an FPI fellowship (PRE2019-090360), and V.C.-M. acknowledges support from the Ramón y Cajal program (RYC2019-02649-I), both from MCIN/AEI/10.13039/501100011033 and “European Social Fund (ESF) Investing in your future.” M.R.-D.-D. is recipient of a Martí-Franquès Research Grant Programme (2021PMF-PIPF-2) from Universitat Rovira i Virgili. C.P.-L. is recipient of an FPU fellowship from the Spanish Ministry of Education. J.S.-B. is a recipient of a predoctoral contract for training in health research from the Instituto de Salud Carlos III, co-financed by the ESF (PFIS FI18/00151). S.F.-V. acknowledges support from the Miguel Servet tenue-track program (CP10/00438 and CPII16/00008) from the Fondo de Investigación Sanitaria, co-financed by the ERDF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification

  • Valer, José Antonio
  • Deber, Alexandre
  • Wits, Marius
  • Pimenta-Lopes, Carolina
  • Goumans, Marie-José
  • Rosa, José Luis
  • Sánchez-Duffhues, Gonzalo
  • Ventura, Francesc
Reviewed Preprint: Published from the originalpreprint after peer reviewand assessment by eLife., Heterotopic ossification (HO) occurs following mechanical trauma and burns, or congenitally in patients suffering from fibrodysplasia ossificans progressiva (FOP). Recently, we demonstrated that inhibitors of phosphatidyl-inositol 3-kinase alpha (PI3Kα) may be a useful therapy for patients undergoing HO. In this study, using the already marketed BYL719/Alpelisib/Piqray drug, we have confirmed further these results, detailed the underlying mechanisms of action, and optimized the timing of the administration of BYL719. We found that BYL719 effectively prevents HO even when administered up to three to seven days after injury. We demonstrate in cell cultures and in a mouse model of HO that the major actions of BYL719 are on-target effects through the inhibition of PI3Kα, without directly affecting ACVR1 or FOP- inducing ACVR1R206H kinase activities. In vivo, we found that a lack of PI3Kα in progenitors at injury sites is sufficient to prevent HO. Moreover, time course assays in HO lesions demonstrate that BYL719 not only blocks osteochondroprogenitor specification, but also reduces the inflammatory response. BYL719 inhibits the migration, proliferation and expression of pro-inflammatory cytokines in monocytes and mast cells, suggesting that BYL719 hampers the hyper-inflammatory status of HO lesions. Altogether, these results highlight the potential of PI3Kα inhibition as a safe and effective therapeutic strategy for HO., We acknowledge the support fromPromega R&D. Alexandre Deber is a recipient of a F.P.I. fellowship from the Ministry of Scienceand Innovation (MCIN/AEI/ 10.13039/501100011033). Carolina Pimenta-Lopes is the recipient of aF.P.U. fellowship from the Spanish Ministry of Education. This research was supported by grantsPID2022-141212OA-I00, PDC2021-121776-I00 and PID2020-117278GB-I00 fromMCIN/AEI/10.13039/501100011033, co-funded by FEDER ‘Una manera de hacer Europa’ or‘NextGenerationEU’/PRTR; a grant 202038-30 from La Marató de TV3 and grants from IFOPA (ACTfor FOP) and FOPItalia. MW and MJG are sponsored by the Netherlands Cardiovascular ResearchInitiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, theNetherlands Organization for Health Research and Development, and the Royal NetherlandsAcademy of Sciences), PHAEDRA-IMPACT (DCVA) and DOLPHIN-GENESIS (CVON). GSD is alsosponsored by the Spanish Ministry of Science through the Ramón y Cajal grant RYC2021-030866-Iand the BHF-DZHK-DHF, 2022/23 award PROMETHEUS., Peer reviewed